132 related articles for article (PubMed ID: 589594)
1. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
Rivera G; Green A; Hayes A; Avery T; Pratt C
Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
Bleyer WA; Krivit W; Chard RL; Hammond D
Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
[TBL] [Abstract][Full Text] [Related]
3. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
4. [Hypersensitivity to VM-26].
Köster B; Ritter J; Bode U
Klin Padiatr; 1984; 196(3):178-80. PubMed ID: 6540829
[TBL] [Abstract][Full Text] [Related]
5. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.
Hayes FA; Abromowitch M; Green AA
Cancer Treat Rep; 1985 Apr; 69(4):439-41. PubMed ID: 3857970
[TBL] [Abstract][Full Text] [Related]
6. Preliminary evaluation of VM-26: a new epipodophyllotoxin derivative, in the treatment of urogenital tumours.
Pavone-Macaluso M; Caramia G; Rizzo FP; Messana V
Eur Urol; 1975; 1(1):53-6. PubMed ID: 786645
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
Seiler RW; Vassella F; Markwalder H
Surg Neurol; 1979 Mar; 11(3):237-42. PubMed ID: 473022
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
[TBL] [Abstract][Full Text] [Related]
9. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors of children.
Seiler RW
Helv Paediatr Acta; 1980 Mar; 35(1):51-6. PubMed ID: 7410103
[TBL] [Abstract][Full Text] [Related]
11. Sequential cis-platinum and VM26 in neuroblastoma: laboratory and clinical (OPEC regimen) studies.
Pritchard J; Whelan R; Hill BT
Prog Clin Biol Res; 1985; 175():545-55. PubMed ID: 4039448
[No Abstract] [Full Text] [Related]
12. Use of VM-26 as a single agent in the treatment of renal carcinoma.
Hire EA; Samson MK; Fraile RJ; Baker LH
Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of cis-dichlorodiammine-platinum in the treatment of advanced neuroblastoma].
Ohnuma N; Takahashi H; Maie M; Etoh T; Tanabe M; Kuriyama Y
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2876-80. PubMed ID: 3662544
[TBL] [Abstract][Full Text] [Related]
14. Comparative trial of two teniposide-based combination chemotherapy regimens for the treatment of advanced malignant lymphomas.
O'Connell MJ; Anderson J; Merrill JM; Bennett JM; Glick JH; Berard CW; Neiman RS; Brodovsky HS
Cancer Treat Rep; 1982 Dec; 66(12):2021-5. PubMed ID: 6814757
[TBL] [Abstract][Full Text] [Related]
15. [Use of preparation VM 26 (epipodophyllotoxin) for treating lymphomas in children and adults].
Kondrat'eva NA; Gershanovich ML; Kondrat'ev VB; Lebedev VN; Vialushkin VIa
Vopr Onkol; 1981; 27(4):82-7. PubMed ID: 7015693
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity.
Hayes FA; Green AA; Casper J; Cornet J; Evans WE
Cancer; 1981 Oct; 48(8):1715-8. PubMed ID: 7197189
[TBL] [Abstract][Full Text] [Related]
17. VM-26 as a second drug in the treatment of brain gliomas.
Kessinger A; Lemon HM; Foley JF
Cancer Treat Rep; 1979 Mar; 63(3):511-2. PubMed ID: 427830
[TBL] [Abstract][Full Text] [Related]
18. [Results of a clinical study of an epipodophyllotoxin preparation (VM 26) in children with hemoblastoses].
Kondrat'eva NA; Makhonova LA; Maiakova SA; Vialushkin BIa
Probl Gematol Pereliv Krovi; 1981 Apr; 26(4):12-6. PubMed ID: 7015318
[No Abstract] [Full Text] [Related]
19. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
[No Abstract] [Full Text] [Related]
20. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
